Hamilton Thorne Announces Agreement to Be Acquired by Astorg for CAD$2.25 Per Share in Cash
Hamilton Thorne Announces Agreement to Be Acquired by Astorg for CAD$2.25 Per Share in Cash
- Purchase price of CAD$2.25 per Hamilton Thorne share represents enterprise value of approximately CAD$388 million (US$282 million).
- Represents a premium of approximately 54% to the closing price on the Toronto Stock Exchange ("TSX") of Hamilton Thorne shares on July 19, 2024, the last trading day prior to the announcement of the transaction, and approximately 62% to the 90-day VWAP as of the same date1.
-
The Board of Directors of Hamilton Thorne (with interested directors abstaining) unanimously determined that the transaction is in the best interests of Hamilton Thorne and the transaction consideration to be received by the Hamilton Thorne shareholders is fair, from a financial point of view.
- 每個Hamilton Thorne股票的加元2.25元的購買價格表示約爲38800萬加元(28200萬美元)的企業價值。
- 相對於2024年7月19日多倫多證券交易所("TSX")收盤價的溢價約爲54%,與相同日期1的90天成交量加權平均價("VWAP")的溢價約爲62%。
- 鑑於交易是從財務角度出發對Hamilton Thorne和Hamilton Thorne股東而言最爲公平和最符合利益的,哈密爾頓·索恩(Hamilton Thorne)的董事會(感興趣的董事迴避)一致確定此次交易符合最佳利益。
BEVERLY, Mass. and TORONTO, July 22, 2024 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd (TSX: HTL) ("Hamilton Thorne" or the "Company"), a leading provider of precision instruments, consumables, software, and services to the Assisted Reproductive Technologies ("ART"), research, and the cell biology space, today announced that it has entered into a definitive arrangement agreement dated July 21, 2024 (the "Arrangement Agreement") with an acquisition vehicle (the "Purchaser") managed by Astorg, a leading private equity firm with an extensive track record in global healthcare investments, whereby the Purchaser has agreed to acquire 100% of the issued and outstanding common shares (the "Company Shares") of the Company (the "Transaction").
2024年7月22日,馬薩諸塞州貝弗利和多倫多 – Hamilton Thorne Ltd (TSX: HTL)(“Hamilton Thorne”或“公司”)是高精度儀器、耗材、軟件和服務的領先提供商,爲輔助生殖技術(“ART”)、研究和細胞生物學領域提供具有可靠品牌的產品組合,今日宣佈已於2024年7月21日簽署了一項確定性協議(“安排協議”)與Astorg管理的收購方(“買方”)達成協議,Astorg是一家領先的私募股權公司,在全球醫療保健投資領域具有廣泛的投資業績,買方同意收購公司(“交易”)發行和流通的全部普通股(“公司股份”)。
Under the terms of the Arrangement Agreement, Hamilton Thorne shareholders, other than the Rollover Shareholders (as defined below) with respect to their Rollover Shares (as defined below), will receive C$2.25 in cash per Company Share (the "Transaction Consideration") on completion of the Transaction, corresponding to an enterprise value of approximately CAD$388 million (US$282 million) inclusive of the debt. After a comprehensive review of alternatives, and upon the recommendation of an independent special committee (the "Special Committee") of the board of directors of Hamilton Thorne (the "Board"), the Board (with interested directors abstaining) unanimously determined that the Transaction is in the best interests of Hamilton Thorne and the Transaction Consideration to be received by the Hamilton Thorne shareholders (other than the Interested Parties (as defined below)) is fair, from a financial point of view.
根據安排協議的條款,除與其翻滾股票(如下文所定義)相關的翻滾股東(如下文所定義)之外,哈密爾頓索恩的股東將在交易完成時每股以2.25加元的現金獲得("交易對價")公司股份,相當於約爲38800萬加元(28200萬美元)的企業價值,包括債務。經過全面審查並在獨立特別委員會("董事會")的建議下,董事會(感興趣的董事迴避)一致確定交易對哈密爾頓·索恩最爲公平且最符合利益。
Simultaneously with entering into the Arrangement Agreement, the Purchaser has entered into a binding letter of intent (the "Acquisition LOI"), which is expected to be superseded by a definitive acquisition agreement (the "Acquisition Definitive Agreement") in agreed form, to acquire the ART product portfolio of Cook Medical ("Cook ART"), a leading provider of IVF consumables for the ART space with a portfolio of trusted brands including ovum aspiration needles, catheters, pipettes, equipment, and other specialty products (the "Acquisition").
與達成安排協議同時,買方已簽署了一份有約束力的意向書(“收購意向書”),預計將以規定的形式簽署明確的收購協議(“明確收購協議”),收購Cook Medical(“Cook ART”)的ARt產品組合,Cook ART是爲ARt領域提供IVF耗材的領先提供商,擁有卵泡穿刺針、導管、移液器、設備和其他專業產品等可靠品牌(“收購”)。
Astorg intends to combine Hamilton Thorne and Cook ART following the completion of the Acquisition and the Transaction.
Astorg打算在完成收購和交易後合併Hamilton Thorne和Cook ARt。
Key Transaction Highlights
關鍵交易亮點
- The Transaction Consideration represents a premium of approximately 54% to the closing price on the TSX of the Company Shares on July 19, 2024, the last trading day prior to the announcement of the Transaction.
- The Transaction Consideration also represents a premium of approximately 52% to the 30-day volume weighted average price ("VWAP") of the Company Shares as of July 19, 2024, the last trading day prior to the announcement of the Transaction, and approximately 62% to the 90-day VWAP as of the same date1.
- The Transaction Consideration presents immediate liquidity and certain value to Hamilton Thorne shareholders (other than the Rollover Shareholders with respect to their Rollover Shares) at a compelling price.
- 交易對價相當於2024年7月19日公司股份在TSX收盤價的約54%的溢價。
- 交易對價也相當於2024年7月19日公司股份的30天成交量加權平均價格("VWAP")的約52%,並相當於同一日期1的90天VWAP的約62%。
- 交易對價以具有強大吸引力的價格向哈密爾頓·索恩股東提供了直接的流動性和確定的價值。
David Wolf, Executive Chair of Hamilton Thorne, said, "Hamilton Thorne believes the proposed Transaction will provide compelling and certain value at an attractive premium to our shareholders. Astorg, with a proven track record of investing in MedTech companies with a focus on growth and innovation, will be a strong partner and trusted steward of Hamilton Thorne as the Company enters this next phase."
Hamilton Thorne的執行主席David Wolf說:“Hamilton Thorne相信擬議中的交易將爲我們的股東提供有吸引力和明確的價值,且溢價優惠。Astorg投資於醫療技術公司並專注於增長和創新,在公司進入下一階段時將成爲強有力的合作伙伴和信任的管理者。”
Dr. Kate Torchilin, Chief Executive Officer of Hamilton Thorne, said, "Hamilton Thorne's mission since our inception has been to deliver high quality, innovative, and reliable equipment and consumables and strong technical support to laboratories in the IVF/ART and adjacent spaces, and to enable our customers to deliver better outcomes to patients globally. By partnering with Astorg and joining forces with Cook ART, we expect to be well-positioned to better serve doctors, embryologists, researchers, and patients with a more comprehensive offering."
Hamilton Thorne的首席執行官Kate Torchilin博士說:“自從我們成立以來,哈密爾頓·索恩的任務一直是爲IVF / ARt和相關領域的實驗室提供高質量,創新和可靠的設備和消耗品以及強大的技術支持,以使我們的客戶更好地服務世界各地的患者。通過與Astorg合作並與Cook ARt聯合,我們期望能夠更好地服務醫生,胚胎學家,研究人員和患者,提供更全面的產品。”
Olivier Lieven and Tobias Nordblom, Managing Directors of Astorg, said, "We are pleased to support Hamilton Thorne's vision of transforming the global fertility industry through innovative and quality-driven products and services. The achievements of the Hamilton Thorne team and the Company's strong reputation for quality and innovation are impressive. We look forward to leveraging our expertise in building healthcare businesses to bring Cook ART together with Hamilton Thorne to further enhance the effectiveness and accessibility of ART and IVF treatments and better support families on their fertility journeys."
Astorg的董事總經理Olivier Lieven和Tobias Nordblom表示:“我們很高興支持Hamilton Thorne的願景,通過創新和質量驅動的產品和服務來改變全球生育行業。Hamilton Thorne團隊的成就和公司在質量和創新方面的良好聲譽令人印象深刻。我們期待着利用我們在醫療保健行業業務建設方面的專業知識,將Cook ART與Hamilton Thorne合併,進一步提高ARt和IVF治療的效果和可訪問性,更好地支持家庭生育之旅。”
Additional Transaction Details
其他交易細節
The Transaction will be implemented by way of a Canadian statutory plan of arrangement pursuant to the Business Corporations Act (Ontario). Under the terms of the Arrangement Agreement, Astorg will acquire all of the issued and outstanding Company Shares, with each shareholder of the Company, other than the Rollover Shareholders with respect to their Rollover Shares, receiving the Transaction Consideration for each Company Share they hold. In connection with the Transaction, each outstanding option of the Company will be cashed-out based on its in-the-money value and each outstanding restricted share unit of the Company will be cancelled in exchange for the Transaction Consideration.
交易將通過加拿大安大略省公司業務法中的加拿大法定計劃實施。根據安排協議的條款,Astorg將獲得已發行和流通的公司股份的全部權益,公司的每個股東(與轉讓有關的翻滾股東除外)將收到他們持有的每個公司股份的交易對價。與交易有關的每個公司期權將根據其內在價值折現,每個待定限制性股票單位將取消並換取交易對價。
At the closing of the Transaction, Daniel Thorne and FAX Capital Corp. ("FAX Capital") (collectively, the "Rollover Shareholders") have agreed to effectively roll, in the aggregate, approximately 21.3 million Company Shares (the "Rollover Shares") at an implied value per Company Share equal to the Transaction Consideration and will directly or indirectly acquire equity in the resulting combined entity. FAX Capital and affiliated entities have agreed to roll the entirety of their existing position (which represents approximately 11.5% of the outstanding Company Shares) and also have an option to, directly or indirectly, make an additional US$10 million investment in such entity. Mr. Thorne has agreed to roll approximately 3.6 million Company Shares, which represents approximately 18% of his Company Shares, and approximately 2.4% of the outstanding Company Shares.
在交易關閉時,Daniel Thorne和FAX Capital Corp。("FAX Capital")(統稱爲"翻滾股東")已同意有效轉讓約2130萬公司股份("翻滾股份"),股價對應每個公司股份的交易對價,將直接或間接收購此處相關的股權。 FAX Capital和附屬實體已同意轉讓他們全部現有持股(佔公司股份的約11.5%),並且還有一個選擇,可以通過直接或間接方式向此類公司進行1000萬美元的其他投資。 Thorne先生已同意轉讓約360萬公司股份,相當於其公司股份的約18%和約佔流通公司股份的2.4%。
The Acquisition LOI in connection with the Acquisition is expected to be superseded by the Acquisition
Definitive Agreement following compliance with the terms of the Acquisition LOI, including the expiration of a statutory waiting period of approximately 30 days.
與收購有關的LOI預計將在符合收購LOI的條款,包括在約30天的法定等待期到期後("MI 61-101"特別交易中保護少數股東的多邊工具條例)之後被收購明確代表取代。
交易完成要求其中包括(但不限於):(i)哈密爾頓·索恩股東在預期於2024年9月舉行的特別會議("公司會議")上投出的三分之二的投票,(ii)公司會議上的公司股東票數的多數(不包括根據多邊工具條例61-101中規定的"業務組合"的少數股權持有人所投的票數)投票通過。
Completion of the Transaction is, among other customary matters, subject to:
交易完成要求其中包括(但不限於):(i)哈密爾頓·索恩股東在預期於2024年9月舉行的特別會議("公司會議")上投出的三分之二的投票,(ii)公司會議上的公司股東票數的多數(不包括根據多邊工具條例61-101中規定的"業務組合"的少數股權持有人所投的票數)投票通過。
- Approval by (i) at least two-thirds of the votes cast by Hamilton Thorne shareholders at a special meeting (the "Company Meeting") expected to be held in September 2024, and (ii) a majority of the votes cast by the Company shareholders at the Company Meeting (excluding the votes cast by persons whose votes may not be included in determining minority approval of a "business combination" in accordance with Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"))
- Court approval of the Transaction
- Simultaneous completion of the Acquisition, subject to certain limited exceptions
- Completion of all required regulatory approvals relating to the Transaction and the Acquisition
- 預計於2024年9月召開的特別股東大會("公司會議")需要獲得至少兩三分之一的漢密爾頓索恩股東所投票數的贊同,並在公司會議上獲得公司股東以多數投票數的贊同(不包括根據《多邊機構61101 - 保護少數股東在特殊交易中的權益 》("MI 61-101")不得計入少數股東批准"業務合併"的投票權的人所投票數)。
- 交易獲法院批准
- 以某些有限的例外條件爲前提,完成收購的同時
- 完成與交易和收購相關的所有所需監管批准
Additional details of the Transaction will be described in the management information circular that will be mailed to the Company shareholders (the "Company Circular") in connection with the Company Meeting to approve the Transaction. Additional information regarding the terms of the Arrangement Agreement, the background to the Transaction, the rationale for the recommendations made by the Special Committee and how shareholders can participate in and vote at the Company Meeting will be provided in the Company Circular.
交易的所有其他細節將在將會發給公司股東的管理信息通函(“公司通函”)中描述,以批准交易會議爲連接。有關安排協議的條款,交易背景,特別委員會的建議理由以及股東如何參與和在公司會議上投票的其他信息將在公司通函中提供。
All of the directors and officers of the Company together with certain shareholders of the Company, who collectively own approximately 27.7% of the outstanding Company Shares, have entered into voting and support agreements pursuant to which they have agreed to vote their Company Shares in favor of the Transaction.
公司的全部董事和高管以及公司的某些股東共計持有公司股份的約27.7%已簽署了投票和支持協議,根據該協議,他們同意投票支持交易。
The Arrangement Agreement contains customary terms and conditions, including non-solicitation provisions which are subject to the Company's right to consider and accept a superior proposal that satisfies certain customary requirements and is subject to a matching right in favor of Astorg. The Arrangement Agreement also provides for the payment of a termination fee of CAD$13.5 million in certain circumstances, including where the Company has accepted a superior proposal and terminates the Arrangement Agreement.
與交易有關的安排協議包含慣例條款和條件,包括禁止散播款項,但公司有權考慮並接受滿足某些慣例要求的更好方案,並享有與Astorg有關的匹配權。安排協議還規定,在某些情況下(包括公司接受更好方案並終止安排協議的情況下)支付CAD $ 1350萬的終止費。
A copy of the Arrangement Agreement will be available through the Company's filings with the securities regulatory authorities in Canada on SEDAR+ at .
安排協議的副本將通過在加拿大證券監管機構的SEDAR+的公司文件中通過。
In connection with the closing of the Transaction, the Company Shares will be delisted from the TSX and the Company will apply to cease to be a reporting issuer.
交易完成後,公司股份將被從tsx中除牌,並申請退出報告人身份。
Recommendation of the Special Committee and the Board
特別委員會和董事會的建議
The Special Committee, comprised of Feng Han, Karen Firestone and Bruno Maruzzo (each of whom is an independent director of the Company), after receiving legal and financial advice, including the fairness opinions from the financial advisors discussed below, has unanimously recommended that the Board approve the Arrangement Agreement having determined, among other things, that the Transaction Consideration to be received by the Company shareholders (other than the Interested Parties) pursuant to the Transaction is fair, from a financial point of view.
特別委員會是由Feng Han,Karen Firestone和Bruno Maruzzo組成的(他們中的每一個都是公司的獨立董事),在獲得法律和財務建議(包括下面討論的財務顧問的公正意見)後,已經一致建議董事會批准安排協議,已經論定過,交易對公司股東(除利益相關方)收到的交易考慮來說是公正的,從財務角度來看。
The Special Committee has obtained a fairness opinion from each of Piper Sandler & Co. (who acted as financial advisor to the Company in connection with the Transaction) and Stifel GMP (who acted as independent financial advisor to the Special Committee in connection with the Transaction) to the effect that, as of the date of the Arrangement Agreement, and subject to the assumptions, limitations and qualifications on which such opinions are based, the Transaction Consideration to be received by the Company shareholders (other than the Interested Parties) pursuant to the Transaction is fair, from a financial point of view.
特別委員會已經獲得了Piper Sandler&Co提供的公平意見(他們在與交易有關的公司的財務顧問中擔任角色),以及Stifel GMP提供的公正的財務顧問在與交易有關的特別委員會中擔任角色,並已就安排協議的日期作出裁定,在前提、限制和基此類意見的資格的情況下,除了利益相關方之外的公司股東將收到交易考慮,從財務角度來看是公正的。
After receiving the recommendations of the Special Committee, and the fairness opinions discussed above, the disinterested members of the Board, including a representative of Special Situations Life Sciences Fund LP, have unanimously determined (i) that the Transaction Consideration to be received by the Company shareholders (other than the Interested Parties) pursuant to the Transaction is fair, from a financial point of view; (ii) that the Transaction is in the best interests of the Company; (iii) that the Transaction and the entering into of the Arrangement Agreement and all ancillary agreements are authorized and approved; and (iv) to recommend to the Company shareholders (other than the Interested Parties) that they vote in favor of the resolution to approve the Transaction at the Company Meeting. Special Situations Life Sciences Fund LP exercises control or direction over 14,012,365 Company Shares.
在收到特別委員會的建議和上述的公正意見後,董事會的無利益相關成員一致決定(i)公司股東(除利益相關方)將收到交易考慮,從財務角度來看是公正的;(ii)交易符合公司最大利益;(iii)認可並批准交易以及所有附屬協議;和(iv)建議公司股東(除利益相關方)在公司會議上投票贊成批准交易的決議。Special Situations Life Sciences Fund LP的代表成員一致決定。Special Situations Life Sciences Fund LP控制或負責14012365公司股份。
Additional details concerning the rationale for the recommendations made by the Special Committee and the Board, including copies of the fairness opinions prepared by the financial advisors, will be set out in the Company Circular to be filed and mailed to the Company shareholders in the coming weeks and which will be available under Hamilton Thorne's profile on SEDAR+ at .
有關特別委員會和董事會的建議的進一步詳細信息(包括財務顧問準備的公正意見的副本)將在公司環中規定,並將在未來幾周內通過在Hamilton Thorne的SEDAR+檔案中公佈和發送給公司股東。
Multilateral Instrument 61-101
多邊監管機構61-101
The Transaction constitutes a "business combination" under MI 61-101 for the Company as, among other things, the Rollover Shareholders are related parties and they will receive rollover equity consideration in consideration for their Rollover Shares.
根據MI 61-101的要求,交易對於公司而言構成“業務組合”,因爲Rollover股東是關聯方,他們將獲得換股權益考慮。
As required by MI 61-101, the Company will seek the requisite majority of the minority approval of the Transaction from the Company shareholders at the Company meeting, excluding the votes of each "interested party" (as defined in MI 61-101) (collectively, the "Interested Parties") whose votes are required to be excluded for the purposes of "minority approval" under MI 61-101 in the context of a "business combination" (which for these purposes will include the Rollover Shareholders).
按照MI 61-101的要求,公司將從公司股東那裏尋求交易的少數股東必需的多數批准,除了每個“利益相關方”(在MI 61-101中定義)的投票必須排除在“業務組合”的情況下爲了多數同意而要求的情況(本次交易將包括Rollover股東)。
Advisors
顧問
Piper Sandler & Co. is acting as exclusive financial advisor to the Company. Stifel GMP is acting as independent financial advisor to the Special Committee. Dentons Canada LLP is acting as legal advisor to the Company. Norton Rose Fulbright Canada LLP is acting as legal advisor to the Special Committee. Jefferies Securities, Inc. is acting as exclusive financial advisor to Astorg. Stikeman Elliott LLP and Weil, Gotshal & Manges LLP are acting as legal advisors to Astorg.
Piper Sandler&Co擔任公司的獨家財務顧問,Stifel GMP則擔任特別委員會的獨立財務顧問。Dentons Canada LLP擔任公司的法律顧問。Norton Rose Fulbright Canada LLP擔任特別委員會的法律顧問。Jefferies Securities,Inc.擔任Astorg的獨家財務顧問。Stikeman Elliott LLP和Weil Gotshal&Manges LLP擔任Astorg的法律顧問。
Early Warning Disclosure
提前預警披露
Further to the requirements of National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues, Daniel Thorne and FAX Capital will file separate early warning reports in connection with their participation in the Transaction as a Rollover Shareholders and for which they entered into voting and support agreements pursuant to which they have each agreed, subject to the terms thereof, to support and vote all of the Company Shares that they own or control. FAX Capital owns or controls 11.5% of the outstanding Company Shares. Mr. Thorne owns or controls 13.2% of the outstanding Company Shares.
根據《國家儀器62-103提前警告系統及相關接管出價和內幕交易報告問題》,作爲Rollover持有人蔘與交易的Daniel Thorne和FAX Capital將分別提交獨立提前警告報告,他們根據該報告已進入者投票和支持協議,其中他們每個都同意,在此項條件下支持和投票他們擁有或控制的所有公司股票。FAX Capital擁有或控制公司股份的11.5%。Thorne先生擁有或控制公司股份的13.2%。
Copies of the early warning reports will be available under the Company's SEDAR+ profile at , or may, with respect to the early warning report filed by Daniel Thorne, be obtained by contacting Mr. Thorne at 978.921.2050 and, with respect to the early warning report filed by FAX Capital, be obtained by contacting Ryan Caughey, General Counsel and Corporate Secretary of FAX Capital at 647.696.4679.
提前警告報告的副本將在公司的SEDAR+檔案中公開,或可以聯繫FAX Capital的總法律顧問和公司秘書Ryan Caughey(電話:647.696.4679),獲取關於Daniel Thorne提交的提前警告報告的信息(電話:978.921.2050)。
FAX Capital is a corporation incorporated under the laws of Canada and its head office is located at 2 Bloor Street East, Suite 701, Toronto, Ontario, M4W 1A8. The address of Mr. Thorne is c/o Hamilton Thorne Ltd., 100 Cummings Centre, Suite 465E, Beverly, Massachusetts, 01915 USA.
FAX Capital是以加拿大法律爲基礎的公司,總部位於安大略省多倫多市Bloor街東2號,701號套房1A8。Thorne先生的地址爲100 Cummings Centre,Suite 465E,Beverly,Massachusetts,01915 USA,合法代表爲Hamilton Thorne Ltd。
About Hamilton Thorne
有關Hamilton Thorne的詳細信息
Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and the cell biology space. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, IVFtech, Embryotech Laboratories, Tek-Event, Microptic, and Gynetics brands, through its growing sales force and distributors worldwide. Hamilton Thorne customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.
Hamilton Thorne是全球領先的精密儀器、耗材、軟件和服務供應商,可降低成本、提高生產力、改善結果並實現輔助生殖技術(ART)、研究和細胞生物學領域的突破。Hamilton Thorne在全球範圍內通過其不斷增長的銷售團隊和經銷商以Hamilton Thorne、Gynemed、Planer、IVFtech、Embryotech Laboratories、Tek-Event、Microptic和Gynetics品牌銷售其產品和服務。Hamilton Thorne的客戶群包括生育診所、大學研究中心、動物繁殖設施、製藥公司、生物技術公司和其他商業和學術研究機構。
For more information about Hamilton Thorne:
更多有關Hamilton Thorne 的信息:
About Astorg
關於Astorg Astorg是一家領先的歐洲股權投資公司,管理着超過220億歐元的資產,並在全球醫療保健投資方面擁有廣泛的業績。Astorg與企業家和管理團隊合作,收購總部位於歐洲或美國的全球領先公司,併爲其提供實現增長目標所需的戰略指導,治理和資本。憑藉獨特的企業家文化,長期的股東觀點和精簡的決策機構,Astorg在醫療保健,軟件,技術,商業服務和技術爲基礎的工業公司方面擁有有價值的行業專業知識。Astorg總部位於盧森堡,在倫敦,巴黎,紐約,法蘭克福和米蘭設有辦事處。
Astorg is a leading pan-European private equity firm with over €22 billion of assets under management and an extensive track record in global healthcare investments. Astorg works with entrepreneurs and management teams to acquire market leading global companies headquartered in Europe or the US, providing them with the strategic guidance, governance and capital they need to achieve their growth goals. Enjoying a distinct entrepreneurial culture, a long-term shareholder perspective and a lean decision-making body, Astorg has valuable industry expertise in healthcare, software, technology, business services and technology-based industrial companies. Headquartered in Luxembourg, Astorg has offices in London, Paris, New York, Frankfurt, and Milan.
Astorg是一家領先的泛歐洲私募股權公司,管理着超過220億歐元資產,並在全球醫療保健投資方面具有廣泛的投資業績。Astorg與企業家和管理團隊合作,收購總部位於歐洲或美國的領先全球企業,爲它們提供戰略指導、治理和資本,以實現它們的增長目標。享有獨特的創業文化、長期的股東視角和精簡的決策機構,Astorg在醫療保健、軟件、技術、商業服務和基於技術的工業公司方面具有有價值的行業專業知識。總部位於盧森堡,Astorg在倫敦、巴黎、紐約、法蘭克福和米蘭設有辦事處。
For more information about Astorg: . Follow Astorg on LinkedIn.
本新聞稿包含“前瞻性信息”和“前瞻性聲明”(統稱爲“前瞻性信息”),目的是提供有關管理層當前對未來計劃和期望的期望的信息。讀者應當注意,依賴此類信息可能不適用於其他目的。任何此類前瞻性信息或聲明(“FLS”)均可能由諸如“建議”,“預計”,“打算”,“可能”,“將”和類似表達的單詞所確定。本新聞稿中包含或涉及的FLS包括但不限於有關Transaction或Acquisition的擬議時間和各種步驟,公司股東在公司會議上持有和批准Transaction以及Transaction完成後的結果,公司和Cook Medical的ARt業務的組合,由此產生的ARt / IVF業務以及對客戶,未來創新和增長潛力的影響以及Transaction和Acquisition完成的可能性。
Forward-Looking Statements
前瞻性聲明
This press release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Such forward-looking information or statements ("FLS") are provided for the purpose of providing information about management's current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes. Any such FLS may be identified by words such as "proposed", "expects", "intends", "may", "will", and similar expressions. FLS contained or referred to in this press release includes, but is not limited to, statements regarding the proposed timing and various steps contemplated in respect of the Transaction or the Acquisition, the holding of and approval by the Company shareholders of the Transaction at the Company Meeting and the results of the completion of the Transaction, the combination of the Company and Cook Medical's ART business, the resulting ART / IVF business, and resulting benefits to customers, future innovation and growth potential, and the likelihood that the Transaction and the Acquisition will be consummated.
本新聞稿包含“前瞻性信息”和“前瞻性聲明”(統稱爲“前瞻性信息”),旨在提供有關管理層有關未來計劃和期望的信息。讀者應注意,在其他場景下依賴此類信息時存在風險。任何此類前瞻性信息均可以用“擬議”、“預計”、“意向”、“可能”、“將”等表達方式來辨識。此新聞稿中包含的前瞻性信息包括但不限於,與交易或收購有關的擬議時間和各種步驟、公司股東在公司會議上的持有和批准交易的結果、公司和Cook Medical的ARt業務組合、由此產生的ARt/IVF業務以及客戶的相關收益、未來的創新和成長潛力以及交易和收購將會完成的可能性。
FLS is based on a number of factors and assumptions which have been used to develop such statements and information, but which may prove to be incorrect. Although the Company believes that the expectations reflected in such FLS is reasonable, undue reliance should not be placed on FLS because the Company can give no assurance that such expectations will prove to be correct. Factors that could cause actual results to differ materially from those described in such FLS include, without limitation, the following factors, many of which are beyond the Company's control and the effects of which can be difficult to predict: (a) the possibility that the Transaction will not be completed on the terms and conditions, or on the timing, currently contemplated, and that it may not be completed at all, due to a failure to obtain or satisfy, in a timely manner or otherwise, required shareholder, court and regulatory approvals and other conditions of closing necessary to complete the Transaction or for other reasons; (b) risks related to the nature of the Acquisition LOI, including the failure to enter into the Acquisition Definitive Agreement; (c) the possibility of adverse reactions or changes in business relationships resulting from the announcement or completion of the Transaction or the Acquisition; (d) risks relating to the abilities of the parties to satisfy conditions precedent to the Transaction and the Acquisition; (e) a third party superior proposal materializing prior to the completion of the Transaction; (f) credit, market, currency, operational, liquidity and funding risks generally and relating specifically to the Transaction and the Acquisition, including changes in economic conditions, interest rates or tax rates; (g) risks related to the Company resulting from the combination of the Company and Cook Medical's ART business in retaining existing customers and attracting new customers, retaining key personnel, executing on growth strategies, advancing its product line and protecting its intellectual property rights and proprietary information; (h) changes and trends in the Company's industry and the global economy; and (i) the identified risk factors included in the Company's public disclosure, including the annual information form dated March 27, 2024, which is available on SEDAR+ at . If any of these risks or uncertainties materialize, or if the assumptions underlying the FLS prove incorrect, actual results or future events might vary materially from those anticipated in the FLS. Although the Company has attempted to identify important risk factors that could cause actual results to differ materially from those contained in FLS, there may be other risk factors not presently known to the Company or that the Company presently believes are not material that could also cause actual results or future events to differ materially from those expressed in such FLS. The FLS in this press release reflect the current expectations, assumptions, judgements and/or beliefs of the Company based on information currently available to the Company, and are subject to change without notice.
前瞻性信息是基於許多因素和假設進行了分析和擬定,但這些因素和假設可能被證明是錯誤的。儘管公司認爲此類前瞻性信息是合理的,仍然不應過分依賴它們,因爲公司不能保證此類期望將被證明是正確的。導致實際結果與該等前瞻性信息描述的結果不一致的因素包括但不限於以下因素:(a)交易可能不會按照目前預期的條款、條件或時間完成,可能完全不會完成,這是由於沒有及時或其他方面滿足了交易完成所需的,包括股東、法院和監管機構的批准等關閉的其他條件,或由於其他原因;(b)與收購意向書的性質相關的風險,包括未能簽署收購明確協議;(c)由於宣佈或完成交易或收購而導致的不良反應或業務關係的變化;(d)相關各方滿足交易和收購先決條件的能力;(e)在完成交易之前出現第三方更好的提議;(f)信貸、市場、貨幣、業務、流動性和資金風險,通常涉及交易和收購、經濟狀況、利率或稅率的變化;(g)由公司被併購的Cook Medical ARt業務和公司組合帶來的風險,包括在保留現有客戶和吸引新客戶、保留關鍵人員、執行增長戰略、推進產品線和保護知識產權和專有信息方面;(h)公司所在行業和全球經濟的變化和趨勢;(i)包含的風險因素已包含在公司的公開披露中,包括於2024年3月27日發佈的年度信息文件,該文件在SEDAR+上可以獲得。 沒有證券監管機構批准或不批准本新聞發佈內容的內容。 TSX不承擔此發佈的充分性或準確性的責任。
Any FLS speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any FLS, whether as a result of new information, future events or results or otherwise, except as required under applicable securities laws. The FLS contained in this press release are expressly qualified by this cautionary statement. For more information on the Company, please review the Company's continuous disclosure filings that are available at .
了解更多信息,投資者和分析師請聯繫: Kate Torchilin,David Wolf IR@HamiltonThorne.ltd 有關媒體的更多信息,請聯繫: Hamilton Thorne Aiden Woglom,Anne Hart Pro-HamiltonThorne@prosek.com Astorg Samia Hadj Shadj@Astorg.com
No securities regulatory authority has either approved or disapproved of the contents of this news release. The TSX accepts no responsibility for the adequacy or accuracy of this release.
沒有證券監管機構批准或不批准本新聞發佈內容的內容。 TSX不承擔此發佈的充分性或準確性的責任。
For more information, investors and analysts please contact:
了解更多信息,投資者和分析師請聯繫: Kate Torchilin,David Wolf IR@HamiltonThorne.ltd
Kate Torchilin, David Wolf
Hamilton Thorne Ltd.
978-921-2050
IR@HamiltonThorne.ltd
凱特·託奇林,大衛·沃爾夫
Hamilton Thorne Ltd.
978-921-2050
IR@HamiltonThorne.ltd
Glen Akselrod
Bristol Investor Relations
905-326-1888
glen@bristolir.com
Glen Akselrod
Bristol Investor Relations
905-326-1888
glen@bristolir.com
For more information, press please contact:
有關媒體的更多信息,請聯繫: Hamilton Thorne Aiden Woglom,Anne Hart Pro-HamiltonThorne@prosek.com
Hamilton Thorne
Aiden Woglom, Anne Hart
Prosek Partners
Pro-HamiltonThorne@prosek.com
Hamilton Thorne
Aiden Woglom,Anne Hart
Prosek Partners
Pro-HamiltonThorne@prosek.com
Astorg
Samia Hadj
Shadj@Astorg.com
Astorg
Samia Hadj
Shadj@Astorg.com
Prosek Partners
Pro-Astorg@prosek.com
Prosek Partners
Pro-Astorg@prosek.com
1 Premium based on applicable trading-day VWAPs per Bloomberg
1個溢價,基於適用的Bloomberg日交易VWAPs